Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Spine-Tech (SPYN) -- Ignore unavailable to you. Want to Upgrade?

To: Royalcoachman who wrote (213)	12/4/1997 10:56:00 AM
From: John Bloxom	Read Replies (1) \| Respond to of 242

Uh, David... A 12.9% compounded growth rate on sequential quarters equals a year over year growth rate of 62%; that rate, in turn will command a 52 week high multiple way in excess of 38x. Maybe you should consider changing out the batteries in that calculator of yours. Or, if it is a solar model, try moving closer to a window. Regards, John

To: Royalcoachman who wrote (213)	12/6/1997 6:20:00 PM
From: utee	Read Replies (2) \| Respond to of 242

It absolutely amazed me that you would have taken the time to post such a thorough analyses of this company in response to the muddled input and sometimes downright false info that has been posted on this board since it's inception. In particular, a "JBERSHAD" posts regularly on this board - and his major contribution seems to be how many "analysts" are touting this stock as a "buy". If someone posts a fact he doesn't like about this stock - he gets very nasty, like a baby when he loses his binky. Although your post 213 was essentially correct, your forecast of overvaluation of the stock is somewhat low. Generally, a comp[any in this field claiming 25% market for its product is overstating for the IPO, and from my experience, they will not even get 10% of the 25%share of this particular market - too many experienced competitors, inexperienced management, technique requirements, new competeing products , etc. etc. etc. But, thanks for bringing some sanity to this board to what appears to attract a lot of losers Utee

To: Royalcoachman who wrote (213)	12/7/1997 12:34:00 AM
From: ForYourEyesOnly	Respond to of 242

Thank you for your response. We are both busy, so I will keep my response simple. 1. What is the reason that the SPYN product is only to be used in 1/4 of the total number of procedures? 2. Suppose that SYPN gets the 100,000 operations per year, and makes $300M per year in revenue. If they have 15% profits on this, then they will make $45M/year in profits, or about $4.5 per share. At $33/ a share, is this really overvalued? 3. As another poster has kindly pointed out, Q to Q sequential revenue increases of 12% is excellent, and if sustainable would turn into excellent Y to Y revenue increases. Good luck.... THC